-
In clinical practice, patients with atrial fibrillation (AF) duration < 48 hours often undergo cardioversion without systemic anticoagulation.
-
Medications for Risk Reduction of Breast Cancer in Women
-
Primary percutaneous coronary intervention (PCI) is the optimal treatment for patients suffering ST-elevation myocardial infarction (STEMI).
-
Multiple prospective, randomized trials have shown a mortality reduction in patients with reduced left ventricular ejection fraction who undergo prophylactic implantable cardioverter-defibrillator (ICD) therapy.
-
Evidence-based updates in primary care medicine By Louis Kuritzky, MD
-
Pacemaker or defibrillator leads have been shown to have attached thrombi in up to one-third of cases and asymptomatic pulmonary emboli have been documented in up to 20% of patients.
-
Dabigatran is a novel anticoagulant that has been shown to be at least as good as warfarin at preventing thromboembolism in atrial fibrillation (AF).
-
Computed tomography (CT) has evolved significantly in recent years, and is now able to accurately assess coronary arteries for the presence of atherosclerosis in carefully selected patients.
-
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions.
-
Cardiovascular disease (CVD) risk calculators are frequently used by clinicians to guide patient management. Unfortunately, there are more than 100 risk calculators and smaller studies have shown insistencies between them.
